Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of AK139 injection in chronic spontaneous urticaria
CTR20263778Phase 2Active
- Sponsor
- Akeso, Inc.
- Start
- Oct 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of AK139 in chronic idiopathic urticaria (CIU), sponsored by Akeso, Inc.. Started Oct 2026; status: active.
02
Drugs
AK139
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on CTR20263778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263778.